Welcome, Guest. Please login or register.
October 18, 2019, 12:04:44 pm

Login with username, password and session length

 

Members
Stats
  • Total Posts: 223
  • Total Topics: 108
  • Online Today: 10
  • Online Ever: 139
  • (October 31, 2018, 04:13:53 am)
Users Online
Users: 0
Guests: 2
Total: 2

Welcome!

Welcome to the Cancer Health Forums, a round-the-clock discussion area for people who have any type of cancer, their friends and family and others with questions about living with cancer. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Cancer Health Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: An experimental therapy shows promise for colon cancer  (Read 769 times)

Offline iana5252

  • Administrator
  • Newbie
  • *****
  • Posts: 5
    • View Profile
An experimental therapy shows promise for colon cancer
« on: June 07, 2019, 09:32:41 am »
This news came out of ASCO, a big cancer doctor gathering in Chicago held in June every year. Here's some of Cancer Health's coverage of the news.

--------------------------------------------------

An experimental therapy designed to target mutated KRAS proteins showed good activity in a small Phase I study of people with lung cancer, colon cancer and other solid tumors, researchers reported this week at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago.

If these results are confirmed in larger trials, this could be good news for patients because KRAS mutations occur more frequently in lung tumors than other mutations—such as ALK, BRAF and EGFR—targeted by existing drugs. Likewise, only a small proportion of colorectal cancer is targetable by existing medications.

Researchers have identified several so-called driver mutations that contribute to the development of cancer. Mutations involving KRAS, a signaling protein that regulates cell multiplication, are the most common genetic variations in lung cancer. But to date, no medications have been able to successfully target these mutations.

“KRAS has been a target of active exploration in cancer research since it was identified as one of the first oncogenes more than 30 years ago, but it remained undruggable due to a lack of traditional small molecule binding pockets on the protein,” David Reese, MD, executive vice president of research and development at Amgen, said in a company press release. “AMG 510 seeks to crack the KRAS code by exploiting a previously hidden groove on the protein surface.”

Read more...
https://www.cancerhealth.com/article/first-kras-targeted-therapy-shows-promise-lung-colon-cancer

 


© 2019 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.